Discriminant Score for Diagnosing Advanced Fibrosis or Cirrhosis

Objective: The aim of the study was to assess the utility of a modified three-parameter cirrhosis discriminant score (CDS) for diagnosing advanced fibrosis or cirrhosis in patients with evidence of chronic hepatitis C, Methods: We examined liver tissue from 79 patients, Patients with a histological fibrosis score of 0-2 made up group A, and patients with a score of 3 or 4 (advanced fibrosis or cirrhosis) group B.

Results: The modified CDS (possible total score 0-11) was derived from three laboratory parameters: platelets, ALT/AST ratio, and PT, The total score was significantly lower in group A (4.3 +/- 2.0) than in group B (7.9 +/- 1.4) (p < 0.0001), There was a positive correlation between the CDS and histological fibrosis score (r = 0,64,p < 0.0001), With 8 or above as the cutoff value, the CDS had a sensitivity of 46% and a specificity of 98 % for the diagnosis of histological fibrosis scores of 3 or 4.

Conclusions: We conclude that a three-parameter CDS is useful for identifying patients with hepatitis C and a high likelihood of cirrhosis, Patients with a CDS less than or equal to 7 still require histological examination to identify advanced fibrosis or cirrhosis.

Author: BONACINI M, UNIV SO CALIF, RANCHO LOS AMIGOS MED CTR, LIVER UNIT, BLDG 500, 7601 E IMPERIAL HIGHWAY DOWNEY, CA 90242
Source: AMERICAN JOURNAL OF GASTROENTEROLOGY 1997 AUG;92(8):1302-1304

New Hepatitis C Drug Combinations
Combined with interferon and ribavirin, clinical trials on Vertex's telaprevir demonstrate twice the success rate in clearing Hepatitis C in half the time as traditional combination therapy. While this alone is exciting, Vertex is exploring a range of drug combination options for battling the Hepatitis C virus.

Triple Therapy Reduces Hepatitis C Drug Resistance
A review in the February 2010 issue of Gastroenterology sites viral resistance against new medications as incentive for using triple therapy to treat Hepatitis C.

Three HCV Drug Candidates Proceed to Phase II
Hepatitis C drug candidates ABT-450, ABT-333 and ABT-072 move into Phase II testing.